CoChat

DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance

Open access
Schröder, Martin, Renatus, Martin, Liang, Xiaoyou, Meili, Fabian, Zoller, Thomas, Ferrand, Sandrine, Gauter, Francois, Li, Xiaoyan, Sigoillot, Frederic, Gleim, Scott, Stachyra, Therese-Marie, Thomas, Jason R., Begue, Damien, Khoshouei, Maryam, Lefeuvre, Peggy, Andraos-Rey, Rita, Chung, BoYee, Ma, Renate, Pinch, Benika, Hofmann, Andreas, Schirle, Markus, Schmiedeberg, Niko, Imbach, Patricia, Gorses, Delphine, Calkins, Keith, Bauer-Probst, Beatrice, Maschlej, Magdalena, Niederst, Matt, Maher, Rob, Henault, Martin, Alford, John, Ahrne, Erik, Tordella, Luca, Hollingworth, Greg, Thomä, Nicolas H., Vulpetti, Anna, Radimerski, Thomas, Holzer, Philipp, Carbonneau, Seth, Thoma, Claudio R. · 2024 · Nature Communications
Cited by 97

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

Targeted protein degradation (TPD) mediates protein level through small molecule induced redirection of E3 ligases to ubiquitinate neo-substrates and mark them for proteasomal degradation. TPD has recently emerged as a key modality in drug discovery. So far only a few ligases have been utilized for TPD. Interestingly, the workhorse ligase CRBN has been observed to be downregulated in settings of resistance to immunomodulatory inhibitory drugs (IMiDs). Here we show that the essential E3 ligase receptor DCAF1 can be harnessed for TPD utilizing a selective, non-covalent DCAF1 binder. We confirm that this binder can be functionalized into an efficient DCAF1-BRD9 PROTAC. Chemical and genetic rescue experiments validate specific degradation via the CRL4 DCAF1 E3 ligase. Additionally, a dasatinib-based DCAF1 PROTAC successfully degrades cytosolic and membrane-bound tyrosine kinases. A potent and selective DCAF1-BTK-PROTAC (DBt-10) degrades BTK in cells with acquired resistance to CRBN-BTK-PROTACs while the DCAF1-BRD9 PROTAC (DBr-1) provides an alternative strategy to tackle intrinsic resistance to VHL-degrader, highlighting DCAF1-PROTACS as a promising strategy to overcome ligase mediated resistance in clinical settings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-023-44237-4

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 97

Metadata

Authors
Schröder, M., Renatus, M., Liang, X., Meili, F., Zoller, T., Ferrand, S., Gauter, F., Li, X., Sigoillot, F., Gleim, S., Stachyra, T.-M., Thomas, J. R., Begue, D., Khoshouei, M., Lefeuvre, P., Andraos-Rey, R., Chung, B., Ma, R., Pinch, B., Hofmann, A., Schirle, M., Schmiedeberg, N., Imbach, P., Gorses, D., Calkins, K., Bauer-Probst, B., Maschlej, M., Niederst, M., Maher, R., Henault, M., Alford, J., Ahrne, E., Tordella, L., Hollingworth, G., Thomä, N. H., Vulpetti, A., Radimerski, T., Holzer, P., Carbonneau, S., & Thoma, C. R.
Venue
Nature Communications
Published
2024-01-04
Volume
15
Issue
1
Pages
275-275
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4390579643
Cited by
97
References
42
FWCI
11.39
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance. https://app.cochat.ai/papers/10.1038/s41467-023-44237-4
The paper
Schröder, M., Renatus, M., Liang, X., Meili, F., Zoller, T., Ferrand, S., Gauter, F., Li, X., Sigoillot, F., Gleim, S., Stachyra, T.-M., Thomas, J. R., Begue, D., Khoshouei, M., Lefeuvre, P., Andraos-Rey, R., Chung, B., Ma, R., Pinch, B., . . . Thoma, C. R. (2024). DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance. Nature Communications. https://doi.org/10.1038/s41467-023-44237-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.